## Management of Erosive Lichen Planus ### Treatment Hierarchy **Key Point:** Erosive oral lichen planus that fails topical corticosteroid therapy requires systemic corticosteroids to achieve disease control and prevent permanent scarring. ### Rationale for Systemic Corticosteroids The patient has: - **Erosive oral disease** (palate and gingiva involvement) - **Failure of topical therapy** after 6 months - **Functional impairment** (pain with eating) - **Risk of progression** to oral cancer (malignant transformation rate ~1–5% in erosive oral lichen planus) **High-Yield:** Erosive oral lichen planus is considered a potentially malignant disorder and requires more aggressive treatment than non-erosive cutaneous disease. ### Treatment Algorithm ```mermaid flowchart TD A[Lichen Planus Diagnosis]:::outcome --> B{Erosive Oral Disease?}:::decision B -->|No| C[Topical Corticosteroids]:::action B -->|Yes| D[Topical + Systemic Corticosteroids]:::action C --> E{Response in 4-6 weeks?}:::decision D --> F{Response in 4-6 weeks?}:::decision E -->|Yes| G[Continue Topical]:::action E -->|No| H[Add Systemic Corticosteroids]:::action F -->|Yes| I[Taper Systemic, Continue Topical]:::action F -->|No| J[Add Steroid-Sparing Agent]:::action J --> K[Retinoids, Cyclosporine, or Azathioprine]:::action ``` ### Recommended Regimen | Component | Recommendation | |-----------|----------------| | **Topical** | Triamcinolone 0.1% paste or fluocinonide gel TDS | | **Systemic** | Prednisolone 0.5–1 mg/kg/day, taper over 8–12 weeks | | **Adjunct** | Topical anesthetic (benzocaine) for pain relief | | **Monitoring** | Clinical response at 4–6 weeks; reassess for tapering | **Clinical Pearl:** Combination therapy (topical + systemic) is superior to monotherapy in erosive oral lichen planus. Systemic corticosteroids should be tapered gradually to prevent rebound flare. ### Steroid-Sparing Alternatives (if needed) If systemic corticosteroids are contraindicated or patient is steroid-dependent: - **Retinoids** (acitretin 25–50 mg/day) - **Cyclosporine** (topical or systemic) - **Azathioprine** (1–2 mg/kg/day) - **Mycophenolate mofetil** **Warning:** Topical calcineurin inhibitors alone are insufficient for erosive disease; they are reserved for non-erosive cutaneous lichen planus or as adjuncts. ### Monitoring for Malignant Transformation **Key Point:** Patients with erosive oral lichen planus require: - Regular clinical examination every 3–6 months - Biopsy of any suspicious lesions (induration, ulceration, color change) - Patient education on oral hygiene and avoidance of irritants (spicy foods, tobacco, alcohol) [cite:Robbins and Cotran 10e Ch 25; Dermatology Textbook of Freedberg et al. 2e] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.